尽管安进公司的新型减肥药物尚需进一步测试，但其核心产品正持续推动业绩增长。威廉·布莱尔分析师指出，虽然投资者目光聚焦于减肥疗法MariTide，但该药关键的第三阶段试验结果预计要到2027年才能揭晓。在此期间，降胆固醇药物瑞百安与哮喘治疗药Tezspire等核心产品正为短期增长提供动力。
值得注意的是，安进发布的2026年初步营收指引超出市场预期，彰显出现有产品组合的强劲实力。尽管肥胖治疗领域竞争激烈，威廉·布莱尔仍维持"跑赢大盘"评级，认为该股未来仍存重要临床催化剂。当前安进股价涨幅达8.5%。
（本文根据市场公开信息整理，不构成投资建议）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.